Silo pharma shares soar 48% after eu patent grant for ptsd treatment

Silo Pharma Inc. shares skyrocketed 48.55% in after-hours trading Monday to $0.52 following a major intellectual property update tied to its PTSD treatment pipeline.

European patent office greenlights novel preventative therapy for stress-related disorders

The company announced a Rule 71(3) communication from the European Patent Office indicating its intent to grant a patent covering a novel preventative therapy targeting the serotonin 4 (5-HT4) receptor pathway.

The allowed claims are expected to cover major European markets, with Silo Pharma evaluating additional protections, including Unitary Patent coverage and national validations.

The patent, licensed from Columbia University, focuses on preventing stress-induced fear and depressive-like behavior using 5-HT4 receptor agonists, an approach aimed at addressing stress resilience rather than treating symptoms after onset.

CEO Eric Weisblum described the development as a 'high-value milestone' that reinforces the company's positioning in next-generation treatments for stress-related disorders.

Silo Pharma's intellectual property portfolio now supports the advancement of its PTSD-focused program, SPC-15, a key driver for the company's pipeline.

With a market capitalization of approximately $4.98 million, Silo Pharma remains a small-cap biotech with significant volatility in recent months.

Shares closed Monday at $0.36 before the sharp after-hours spike, indicating a high level of investor enthusiasm for the company's progress.